|
시장보고서
상품코드
2051188
폐경 후 골다공증 시장 : 약제 클래스별, 투여 경로별, 판매채널별, 지역별Postmenopausal Osteoporosis Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
폐경 후 골다공증 시장은 2026년에 54억 1,320만 달러로 추정되며, 2033년까지 74억 1,600만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 4.6%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 54억 1,320만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 4.60% | 2033년 시장 규모 예측 : | 74억 1,600만 달러 |
골다공증은 뼈의 양과 골밀도가 감소하여 뼈가 부서지기 쉽고 약해져 취약성 골절이 빈번하게 발생하는 질환입니다. 전 세계적으로 50세 이상 여성 3명 중 1명은 골다공증에 걸릴 위험이 있습니다. 그 원인으로는 호르몬의 변화, 칼슘과 비타민D의 부족을 들 수 있습니다. 골다공증은 폐경 후 고령 여성의 골절 증가와 더불어 운동 기능 저하, 이환율 및 사망률 증가로 이어질 수 있습니다. 여성에서 이 질환과 그에 따른 골량 감소가 발생하는 주요 원인은 에스트로겐 결핍입니다. 기타 중요한 위험 요인으로는 유전, 고령, 저체중, 흡연, 알코올 남용 등이 있습니다. 단백질, 칼슘, 비타민D를 충분히 섭취하면 약물 치료 없이도 폐경 후 골다공증을 예방하는 데 도움이 될 수 있습니다. 의사들은 또한 위험을 줄이기 위해 규칙적인 운동과 흡연과 음주를 피하는 것을 권장하고 있습니다. 폐경 전 여성(자연적으로 폐경기에 접어든 여성)이나 골밀도가 낮거나 다른 위험 요인이 있는 여성은 골밀도와 골강도를 개선하기 위해 에스트로겐이나 약물을 사용하는 것이 권장됩니다.
시장 역학
시장 관계자들 간의 합의 등 무기적 성장 활동 증가는 예측 기간 동안 세계 폐경 후 골다공증 시장의 성장을 견인할 것으로 예측됩니다. 예를 들어, 2022년 6월 10일, 세계 전문 제약기업 Theramex UK Ltd는 생명공학 기업 Enzene Biosciences Limited와 골다공증 항흡수 치료제인 데노수맙(Denosumab)의 등록 및 상업화에 대한 라이선스 및 공급 계약을 체결하였습니다고 발표했습니다. 체결했다고 발표했습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 보고서는 다음과 같은 매개변수(기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략)를 기반으로 세계 폐경 후 골다공증 시장의 주요 기업 프로파일을 작성했습니다.
- 이 보고서는 기업의 마케팅 담당자와 경영진이 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
- 이 세계 폐경 후 골다공증 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가를 포함한 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 폐경 후 골다공증 시장 분석에 사용되는 다양한 전략 매트릭스를 활용하여 의사결정을 원활하게 할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 폐경 후 골다공증 시장 : 약제 클래스별, 2021년-2033년
제5장 세계의 폐경 후 골다공증 시장 : 투여 경로별, 2021년-2033년
제6장 세계의 폐경 후 골다공증 시장 : 유통 채널별, 2021년-2033년
제7장 세계의 폐경 후 골다공증 시장 : 지역별, 2021년-2033년
제8장 경쟁 구도
제9장 섹션
LSH 26.06.17Postmenopausal Osteoporosis Market is estimated to be valued at USD 5,413.2 Mn in 2026 and is expected to reach USD 7,416.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 5,413.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.60% | 2033 Value Projection: | USD 7,416 Mn |
Osteoporosis is a medical condition in which the bones become brittle and fragile due to decreased bone mass and bone mineral density, leading to frequent fragility fractures. Worldwide, one in three women over the age of 50 is at risk of developing osteoporosis. It could be due to hormonal changes or a lack of calcium and vitamin D. Along with increased incidences of fractures in older, postmenopausal women, osteoporosis may often lead to mobility loss and perhaps morbidity and death. A major reason for developing this disease and the associated bone loss in women is estrogen deficiency. Other important risk factors are genetics, advanced age, being underweight, smoking, alcohol abuse, etc. Ample intake of protein, calcium, and vitamin D may help prevent postmenopausal osteoporosis without pharmacologic means. Doctors also suggest regular physical activity and avoiding smoking and alcohol consumption to lower the risk. For premenopausal women (women naturally approaching menopause) and those with low bone density and other risk factors, estrogen and drugs are recommended for improved bone density and strength.
Market Dynamics
Increasing inorganic growth activities such as agreements among market players is expected to drive the growth of the global postmenopausal osteoporosis market over the forecast period. For instance, on June 10, 2022, Theramex UK Ltd, a global specialty pharmaceutical company announced a license and supply agreement with Enzene Biosciences Limited, a Biotechnology company for the registration and commercialization of Denosumab, an antiresorptive treatment for osteoporosis.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global postmenopausal osteoporosis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Paras Biopharmaceuticals Finland Oy, Eli Lilly and Company, TRANSCENTA HOLDING, Amgen, Gedeon Richter Plc., Enzene Biosciences, Samsung BioepisL Radius Health, Inc., Alvotech, and AryoGen Pharmed
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global postmenopausal osteoporosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global postmenopausal osteoporosis market
Market Segmentation
- Global Postmenopausal Osteoporosis Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
- Bisphosphonates
- Selective Estrogen Receptor Modulators (SERMs)
- RANK Ligand Inhibitors
- Anabolic Class
- Calcium Metabolism Modifiers
- Others (Calcitonin, Denosumab, among Others)
- Global Postmenopausal Osteoporosis Market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
- Oral
- Intravenous Route
- Subcutaneous
- Global Postmenopausal Osteoporosis Market By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Postmenopausal Osteoporosis Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Country/Region
- South Africa
- Central Africa
- North Africa
- By Country/Region
- Company Profiles
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Mylan N.V. (Viatris Inc.)
- Fresenius Kabi AG
- Hikma Pharmaceuticals PLC
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- GlaxoSmithKline plc
- Sun Pharmaceutical Industries Ltd
- Ligand Pharmaceuticals Incorporated
- Paras Biopharmaceuticals Finland Oy
- Eli Lilly and Company
- TRANSCENTA HOLDING
- Amgen
- Gedeon Richter Plc.
- Enzene Biosciences
- Samsung BioepisL Radius Health, Inc.
- Alvotech
- AryoGen Pharmed
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Attractiveness Analysis
- Market Opportunities
- Product Launches
- Merger, Acquisition, Collaboration
- Regulatory Guideline and Compliances
- Key Developments
- PEST Analysis
- Technology Landscape
- PORTER's Analysis
- Pricing Analysis (2022)
4. Global Postmenopausal Osteoporosis Market, By Drug Class, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Bisphosphonates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Selective Estrogen Receptor Modulators (SERMs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- RANK Ligand Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Anabolic Class
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Calcium Metabolism Modifiers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Others (Calcitonin, Denosumab, among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
5. Global Postmenopausal Osteoporosis Market, By Route of Administration, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Intravenous Route
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
6. Global Postmenopausal Osteoporosis Market, By Distribution Channel, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segments Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
7. Global Postmenopausal Osteoporosis Market, By Region, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021 - 2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Mylan N.V. (Viatris Inc.)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Fresenius Kabi AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Hikma Pharmaceuticals PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sun Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ligand Pharmaceuticals Incorporated
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Paras Biopharmaceuticals Finland Oy
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- TRANSCENTA HOLDING
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Gedeon Richter Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Enzene Biosciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Samsung BioepisL Radius Health, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alvotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AryoGen Pharmed
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
